Key Insights

Highlights

Treatment Research

9 treatments under study, led by Ponatinib

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

100%

2 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results

Data Visualizations

Phase Distribution

2Total
Phase 3 (2)

Trial Status

Active Not Recruiting1
Recruiting1

Clinical Trials (2)

Showing 2 of 2 trials
NCT06051409Phase 3Recruiting

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)

NCT03589326Phase 3Active Not Recruiting

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Showing all 2 trials

Research Network

Common Treatments

  • Ponatinib1
  • Dexamethasone1
  • Investigators Choice Of Tki1
  • Prednisone1
  • Vincristine1

Active Sponsors

  • Guangzhou Healthquest Pharma Co., Ltd1
  • Ascentage Pharma Group Inc.1
  • Takeda1
  • Takeda Development Center Americas, Inc.1

Top Investigators

Related Conditions

  • Ph All1
  • Leukemia Lymphoblastic Acute Philadelphiapositive1
  • Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Phall1

Activity Timeline